BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36448876)

  • 41. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prevalence of FLT3 internal tandem duplication in adult acute myelogenous leukemia].
    Lee JN; Kim HR; Shin JH; Joo YD
    Korean J Lab Med; 2007 Aug; 27(4):237-43. PubMed ID: 18094582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
    Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
    Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.
    Yamato G; Yamaguchi H; Handa H; Shiba N; Kawamura M; Wakita S; Inokuchi K; Hara Y; Ohki K; Okubo J; Park MJ; Sotomatsu M; Arakawa H; Hayashi Y
    Genes Chromosomes Cancer; 2017 Nov; 56(11):800-809. PubMed ID: 28710806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
    Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
    Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.
    Garg M; Nagata Y; Kanojia D; Mayakonda A; Yoshida K; Haridas Keloth S; Zang ZJ; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ding LW; Alpermann T; Sun QY; Lin DC; Chien W; Madan V; Liu LZ; Tan KT; Sampath A; Venkatesan S; Inokuchi K; Wakita S; Yamaguchi H; Chng WJ; Kham SK; Yeoh AE; Sanada M; Schiller J; Kreuzer KA; Kornblau SM; Kantarjian HM; Haferlach T; Lill M; Kuo MC; Shih LY; Blau IW; Blau O; Yang H; Ogawa S; Koeffler HP
    Blood; 2015 Nov; 126(22):2491-501. PubMed ID: 26438511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
    Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
    [No Abstract]   [Full Text] [Related]  

  • 49. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
    Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
    Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
    Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
    Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
    Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
    Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
    Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Molecular Characteristics and Clinical Features of Adults with
    Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.
    Chauhan PS; Bhushan B; Mishra AK; Singh LC; Saluja S; Verma S; Gupta DK; Mittal V; Chaudhry S; Kapur S
    Med Oncol; 2011 Jun; 28(2):544-51. PubMed ID: 20354824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.
    Wu X; Feng X; Zhao X; Ma F; Liu N; Guo H; Li C; Du H; Zhang B
    Mol Cell Biochem; 2016 Sep; 420(1-2):121-8. PubMed ID: 27435859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.